Research Progress on the Gut–Brain Axis in the Pathogenesis and Progression of Alzheimer’s Disease
DOI:
https://doi.org/10.54097/8yaq6q43Keywords:
Alzheimer’s disease, microbiota–gut–brain axis, gut microbiota, neuroinflammation, microbial metabolites, short-chain fatty acids, fecal microbiota transplantation.Abstract
Memory impairment and broader cognitive decline emerge gradually in Alzheimer’s disease (AD), although amyloid-β deposition, tau abnormalities, and neuroinflammatory changes often develop well before the clinical picture is fully established. Drug therapy can lessen selected symptoms, but it does not prevent continuing neuronal loss, and its long-term value is further limited by adverse effects and inadequate delivery across the blood–brain barrier. These shortcomings have increased interest in the microbiota–gut–brain axis (MGBA) as a framework for studying how intestinal biology may influence the brain. In this framework, microbial products and host responses are transmitted through vagal, endocrine, immune, and metabolic routes, while central nervous system activity can in turn alter intestinal conditions. This review evaluates those reciprocal pathways and discusses the roles of the hypothalamic–pituitary–adrenal axis, inflammatory signaling, short-chain fatty acids, tryptophan-derived metabolites, and trimethylamine N-oxide. It then examines microbial diversity and composition in AD and considers evidence for probiotics, fecal microbiota transplantation, and lifestyle-based intervention. Reports of dysbiosis before overt cognitive decline suggest that microbial change may participate in early disease development rather than simply accompany advanced pathology. That possibility remains unproven because most mechanistic evidence comes from animal models and much of the human literature is cross-sectional. Differences in cohort selection, sampling, and control of confounding variables further weaken causal interpretation. Longitudinal cohorts, integrated multi-omics analysis, and clinically meaningful patient stratification will therefore be essential for determining whether the MGBA can be used in AD prevention or treatment.
Downloads
References
[1] Zhang, X.W., et al., Targeting autophagy in Alzheimer's disease: Animal models and mechanisms. Zool Res, 2023. 44(6): p. 1132–1145.
[2] Botella Lucena, P. and M.T. Heneka, Inflammatory aspects of Alzheimer's disease. Acta Neuropathol, 2024. 148(1): p. 31.
[3] Ma, C., F. Hong, and S. Yang, Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 2022. 27(4).
[4] Ossenkoppele, R., R. van der Kant, and O. Hansson, Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurol, 2022. 21(8): p. 726–734.
[5] De-Paula, V.J., et al., Alzheimer's disease. Subcell Biochem, 2012. 65: p. 329–52.
[6] Passeri, E., et al., Alzheimer's Disease: Treatment Strategies and Their Limitations. Int J Mol Sci, 2022. 23(22).
[7] Ramadan, Y.N., et al., Microbiome Gut-Brain-Axis: Impact on Brain Development and Mental Health. Mol Neurobiol, 2025. 62(8): p. 10813–10833.
[8] Lee, A., et al., [Brain-Gut-Microbiota Axis]. Korean J Gastroenterol, 2023. 81(4): p. 145–153.
[9] Zhuang, M., X. Zhang, and J. Cai, Microbiota-gut-brain axis: interplay between microbiota, barrier function and lymphatic system. Gut Microbes, 2024. 16(1): p. 2387800.
[10] Zhang, T., et al., Gut microbiome-targeted therapies for Alzheimer's disease. Gut Microbes, 2023. 15(2): p. 2271613.
[11] Losno, E.A., et al., Vegan Diet and the Gut Microbiota Composition in Healthy Adults. Nutrients, 2021. 13 (7).
[12] Bauermeister, A., et al., Mass spectrometry-based metabolomics in microbiome investigations. Nat Rev Microbiol, 2022. 20(3): p. 143–160.
[13] Paul, J.K., et al., Unlocking the secrets of the human gut microbiota: Comprehensive review on its role in different diseases. World J Gastroenterol, 2025. 31(5): p. 99913.
[14] Stehle, J.R., Jr., et al., Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults. J Gerontol A Biol Sci Med Sci, 2012. 67(11): p. 1212–8.
[15] Man, A.L., et al., Age-associated modifications of intestinal permeability and innate immunity in human small intestine. Clin Sci (Lond), 2015. 129(7): p. 515–27.
[16] Zhang, D., et al., Short-chain fatty acids in diseases. Cell Commun Signal, 2023. 21(1): p. 212.
[17] Wu, L., et al., Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer's Disease: Signals in Host-Microbe Interplay. Nutrients, 2021. 13(1).
[18] Kettenmann, H., et al., Physiology of microglia. Physiol Rev, 2011. 91(2): p. 461–553.
[19] Hwang, Y.K. and J.S. Oh, Interaction of the Vagus Nerve and Serotonin in the Gut-Brain Axis. Int J Mol Sci, 2025. 26(3).
[20] Piovesana, R., et al., Cholinergic Modulation of Neuroinflammation: Focus on α7 Nicotinic Receptor. Int J Mol Sci, 2021. 22(9).
[21] Gamage, R., et al., Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation. Front Cell Neurosci, 2020. 14: p. 577912.
[22] Ma, L., H.B. Wang, and K. Hashimoto, The vagus nerve: An old but new player in brain-body communication. Brain Behav Immun, 2025. 124: p. 28–39.
[23] Podgorny, O.V. and N.V. Gulyaeva, Glucocorticoid-mediated mechanisms of hippocampal damage: Contribution of subgranular neurogenesis. J Neurochem, 2021. 157(3): p. 370–392.
[24] Wang, G., et al., Corticosterone Impairs Hippocampal Neurogenesis and Behaviors through p21-Mediated ROS Accumulation. Biomolecules, 2024. 14(3).
[25] Kim, D.S., et al., A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. Cell Transplant, 2017. 26(9): p. 1560–1571.
[26] Vogt, N.M., et al., Gut microbiome alterations in Alzheimer's disease. Sci Rep, 2017. 7(1): p. 13537.
[27] Raulin, A.C., et al., ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener, 2022. 17(1): p. 72.
[28] Haney, M.S., et al., APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia. Nature, 2024. 628(8006): p. 154–161.
[29] Kelly, J.R., et al., The role of the gut microbiome in the development of schizophrenia. Schizophr Res, 2021. 234: p. 4–23.
[30] Rothhammer, V., et al., Microglial control of astrocytes in response to microbial metabolites. Nature, 2018. 557(7707): p. 724–728.
[31] Liu, P., et al., Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav Immun, 2019. 80: p. 633–643.
[32] Haran, J.P., et al., Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway. mBio, 2019. 10(3).
[33] Braak, H. and K. Del Tredici, The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain, 2015. 138(Pt 10): p. 2814–33.
[34] Barichella, M., et al., Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. Mov Disord, 2019. 34(3): p. 396–405.
[35] Ren, T., et al., Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease. Front Neurol, 2020. 11: p. 137.
[36] Liu, Z., et al., Effect of the plasma lipidome, immune cells, inflammatory proteins, gut microbiota, and plasma metabolites on Alzheimer's Disease: A two-sample Mendelian randomized study and mediation analysis. Brain Res, 2025. 1869: p. 150009.
[37] An, Y., et al., Bidirectional Two-Sample, Two-Step Mendelian Randomisation Study Reveals Mediating Role of Gut Microbiota Between Vitamin B Supplementation and Alzheimer's Disease. Nutrients, 2024. 16(22).
[38] Schoultz, I., et al., Gut microbiota development across the lifespan: Disease links and health-promoting interventions. J Intern Med, 2025. 297(6): p. 560–583.
[39] You, M., et al., The gut microbiota-brain axis in neurological disorders. MedComm (2020), 2024. 5(8): p. e656.
[40] Jain, A., S. Madkan, and P. Patil, The Role of Gut Microbiota in Neurodegenerative Diseases: Current Insights and Therapeutic Implications. Cureus, 2023. 15(10): p. e47861.
[41] Shen, H., et al., Gut microbiota modulates depressive-like behaviors induced by chronic ethanol exposure through short-chain fatty acids. J Neuroinflammation, 2024. 21(1): p. 290.
[42] Ahmed, H., et al., Microbiota-derived metabolites as drivers of gut-brain communication. Gut Microbes, 2022. 14(1): p. 2102878.
[43] Li, L., et al., Gut microbial-derived indole-3-propionate improves cognitive function in Alzheimer's disease. Sci Adv, 2025. 11(48): p. eadw8410.
[44] Anastassova, N., et al., New Indole-3-Propionic Acid and 5-Methoxy-Indole Carboxylic Acid Derived Hydrazone Hybrids as Multifunctional Neuroprotectors. Antioxidants (Basel), 2023. 12(4).
[45] Connell, E., et al., Circulatory dietary and gut-derived metabolites predict early cognitive decline. Gut Microbes, 2026. 18(1): p. 2649487.
[46] Vogt, N.M., et al., The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. Alzheimers Res Ther, 2018. 10(1): p. 124.
[47] Yaqub, A., et al., Plasma trimethylamine N-oxide (TMAO): associations with cognition, neuroimaging, and dementia. Alzheimers Res Ther, 2024. 16(1): p. 113.
[48] Levine, Z.A., et al., Regulation and aggregation of intrinsically disordered peptides. Proc Natl Acad Sci U S A, 2015. 112(9): p. 2758–63.
[49] Lanz, M., et al., Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model. Mech Ageing Dev, 2022. 204: p. 111668.
[50] Ji, X., et al., Gut microbial metabolites and the brain-gut axis in Alzheimer's disease: A review. Biomol Biomed, 2025. 26(2): p. 240–250.
[51] Iida, T., K. Yanai, and T. Yoshikawa, Histamine and Microglia. Curr Top Behav Neurosci, 2022. 59: p. 241–259.
[52] Chen, C., et al., Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation. Gut, 2022. 71(11): p. 2233–2252.
[53] López-Villodres, J.A., et al., Microbiome Alterations and Alzheimer's Disease: Modeling Strategies with Transgenic Mice. Biomedicines, 2023. 11(7).
[54] Sampson, T.R., et al., Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell, 2016. 167(6): p. 1469–1480.e12.
[55] Sun, J., et al., Fecal microbiota transplantation alleviated Alzheimer's disease-like pathogenesis in APP/PS1 transgenic mice. Transl Psychiatry, 2019. 9(1): p. 189.
[56] Zhang, J., et al., A key role of the subdiaphragmatic vagus nerve in the depression-like phenotype and abnormal composition of gut microbiota in mice after lipopolysaccharide administration. Transl Psychiatry, 2020. 10(1): p. 186.
[57] Cattaneo, A., et al., Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging, 2017. 49: p. 60–68.
[58] Loffredo, L., et al., Effect of the probiotic Escherichia coli Nissle 1917 on serum levels of NADPH oxidase-2 and lipopolysaccharide in patients with Alzheimer's disease. J Alzheimers Dis, 2025. 106(2): p. 774–782.
[59] Akhgarjand, C., et al., Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer's disease: A randomized, double-blind, and placebo-controlled study. Front Aging Neurosci, 2022. 14: p. 1032494.
[60] Kim, J.S., et al., Effect of altered gene expression in lipid metabolism on cognitive improvement in patients with Alzheimer's dementia following fecal microbiota transplantation: a preliminary study. Ther Adv Neurol Disord, 2024. 17: p. 17562864231218181.
[61] Liu, S., et al., Gut Microbiota and Dysbiosis in Alzheimer's Disease: Implications for Pathogenesis and Treatment. Mol Neurobiol, 2020. 57(12): p. 5026–5043.
[62] Dicks, L.M.T., How important are fatty acids in human health and can they be used in treating diseases? Gut Microbes, 2024. 16(1): p. 2420765.
[63] Prajapati, S.K., et al., Protection of Alzheimer's disease progression by a human-origin probiotics cocktail. Sci Rep, 2025. 15(1): p. 1589.
[64] Jamerlan, A.M., S.S.A. An, and J.P. Hulme, Microbial diversity and fitness in the gut-brain axis: influences on developmental risk for Alzheimer's disease. Gut Microbes, 2025. 17(1): p. 2486518.
[65] Zhao, Z., et al., Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome, 2021. 9(1): p. 226.
[66] Solch, R.J., et al., Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: A systematic review. J Neurol Sci, 2022. 434: p. 120166.
[67] Ayten, Ş. and S. Bilici, Modulation of Gut Microbiota Through Dietary Intervention in Neuroinflammation and Alzheimer's and Parkinson's Diseases. Curr Nutr Rep, 2024. 13(2): p. 82–96.
[68] Swanson, D., R. Block, and S.A. Mousa, Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr, 2012. 3(1): p. 1–7.
[69] Li, C., et al., Effects of Physical Exercise on the Microbiota in Irritable Bowel Syndrome. Nutrients, 2024. 16(16).
[70] Clark, A. and N. Mach, Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes. J Int Soc Sports Nutr, 2016. 13: p. 43.
[71] Musiek, E.S. and D.M. Holtzman, Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science, 2016. 354(6315): p. 1004–1008.
[72] Olajide, A.T., et al., From Tradition to Translation: A Critical Appraisal of Bacopa monnieri for Neuroprotection from Preclinical and Clinical Perspectives and Challenges in Utilization. Int J Mol Sci, 2026. 27(12).
[73] Rozera, T., et al., Machine Learning and Artificial Intelligence in the Multi-Omics Approach to Gut Microbiota. Gastroenterology, 2025. 169(3): p. 487–501.
[74] Shang, Y., et al., Targeting the APOE4-driven peripheral-central immune axis: A new frontier for Alzheimer's disease therapy. Pharmacol Res, 2026. 231: p. 108339.
[75] Airola, C., et al., Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy. Antibiotics (Basel), 2023. 12(5).
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

